Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

$HSIC
Medical Specialities
Health Care
Get the next $HSIC alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LASKAWY PHILIP A

(Last) (First) (Middle)
C/O HENRY SCHEIN, INC.
135 DURYEA ROAD

(Street)
MELVILLE NY 11747

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HENRY SCHEIN INC [ HSIC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.01 per share 03/19/2025 S 2,604 D $71.044(1) 24,805 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reflects a weighted average of sales made at prices ranging from $71.01 to $71.05 per share. The Reporting Person, upon request by the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, will provide full information regarding the number of shares sold at each separate price for this transaction.
/s/ Jennifer Ferrero (as attorney-in-fact for Philip A. Laskawy) 03/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $HSIC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSIC

DatePrice TargetRatingAnalyst
2/14/2025$80.00Equal Weight
Wells Fargo
1/6/2025$69.00 → $84.00Underperform → Buy
BofA Securities
12/4/2024$75.00Neutral
Mizuho
7/22/2024$81.00 → $92.00Neutral → Outperform
Robert W. Baird
2/26/2024$78.00Market Perform
Leerink Partners
12/12/2023$71.00 → $82.00Neutral → Overweight
JP Morgan
11/10/2023$70.00Hold → Buy
Stifel
8/8/2022$80.00Sell → Neutral
UBS
More analyst ratings

$HSIC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Received Validation of Net-Zero Science-Based Targets

    Company Commits to Science-Based Targets to Guide Pathway for Achieving Net-Zero Emissions by 2050 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Science Based Targets initiative (SBTi) has approved the Company's near-term and long-term science-based emissions reduction targets and has verified Henry Schein's net-zero science-based target by 2050. "Having joined the Business Ambition for 1.5⁰C initiative in 2021, Henry Schein is pleased to fulfill our commitment to set net-zero emissions reduction targets. Sustainability is deeply rooted in our corporate culture, and we unde

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Will Showcase a Selection of the Company's Comprehensive Solutions for Oral Health Professionals at the 2025 International Dental Show

    Media roundtable sessions: "Conversations with Henry Schein: Exploring the Present and Future of Oral Health" will take place to discuss digitalization in dentistry; Henry Schein will also feature "FDI's Integrated Electronic Health Records Project." The Company will present an expansive portfolio of products and solutions, designed to help oral health professionals enhance practice efficiency and the patient experience, and will offer endodontic hands-on courses with Key Opinion Leaders at the booth. Henry Schein, Inc. (NASDAQ:HSIC) will showcase a selection of its comprehensive business and practice solutions, and provide perspectives on the future of dentistry, during the 2025 Inter

    $HSIC
    Medical Specialities
    Health Care

$HSIC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSIC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSIC
SEC Filings

See more

$HSIC
Leadership Updates

Live Leadership Updates

See more
  • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

    The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

    $CL
    $HSIC
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical Specialities
    Health Care

$HSIC
Financials

Live finance-specific insights

See more
  • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

    Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Announces Strategic Investment by KKR, Board Changes and Provides Preliminary Unaudited Financial Results and 2025 Financial Guidance

    KKR to become 12% common shareholder in Henry Schein Henry Schein and KKR to collaborate on range of value creation opportunities Two KKR representatives with deep sector experience to join the Henry Schein Board as independent directors Separately, Robert J. Hombach, who brings extensive financial and strategic experience in health care, has joined the Henry Schein Board as an independent director Announces preliminary unaudited fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19, and preliminary 2025 financial guidance for full-year non-GAAP EPS of low to mid single digit growth In addition, Henry Schein has increased its share repurchase progra

    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

$HSIC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more